Last reviewed · How we verify
SCAI-001 0.02% eyedrop
SCAI-001 0.02% eyedrop is a Small molecule drug developed by SCAI Therapeutics. It is currently in Phase 2 development. Also known as: Cyclosporine 0.02%.
At a glance
| Generic name | SCAI-001 0.02% eyedrop |
|---|---|
| Also known as | Cyclosporine 0.02% |
| Sponsor | SCAI Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCAI-001 0.02% eyedrop CI brief — competitive landscape report
- SCAI-001 0.02% eyedrop updates RSS · CI watch RSS
- SCAI Therapeutics portfolio CI
Frequently asked questions about SCAI-001 0.02% eyedrop
What is SCAI-001 0.02% eyedrop?
SCAI-001 0.02% eyedrop is a Small molecule drug developed by SCAI Therapeutics.
Who makes SCAI-001 0.02% eyedrop?
SCAI-001 0.02% eyedrop is developed by SCAI Therapeutics (see full SCAI Therapeutics pipeline at /company/scai-therapeutics).
Is SCAI-001 0.02% eyedrop also known as anything else?
SCAI-001 0.02% eyedrop is also known as Cyclosporine 0.02%.
What development phase is SCAI-001 0.02% eyedrop in?
SCAI-001 0.02% eyedrop is in Phase 2.
Related
- Manufacturer: SCAI Therapeutics — full pipeline
- Also known as: Cyclosporine 0.02%
- Compare: SCAI-001 0.02% eyedrop vs similar drugs
- Pricing: SCAI-001 0.02% eyedrop cost, discount & access